Diagnosing Graves’ Disease and Non-Graves Hyperthyroidism Using TSH Receptor Antibody Test versus Non-TSH Receptor Antibody Test Methods of Diagnosis

Background: Differentiating Graves hyperthyroidism from the other causes of hyperthyroidism, using serum TRAb testing is essential step for diagnosis. Objectives: To study importance of TRAb in the diagnosis of Graves’ disease, distinguishing it from thyroiditis, and comparing it with clinical features and other tests such as TPOAb, US thyroid and thyroid scintiscan. Methods: A cross-sectional study was conducted on 120 patients attending endocrine clinicErbil city. Patients were studied on clinical feature basis and investigated with serum TRAb, TPOAb, TSH, Free T4, and Ultrasound examination of thyroid gland. Fisher exact test and Chi Square test of independence, Correlation coefficient and t-test of independence were used. Results: Fifty-two patients were found to have Graves’ disease;There was significant correlation between TRAb positivity and diagnosis of Graves’ disease p 0.05. Conclusion: A positive correlation was found between TRAb titer and positivity and no significant relation between TPOAb levels between Graves’ disease patients compared with thyroiditis patients, respectively.

甲状腺本身病变所致甲亢的核素显像特征

目的甲状腺功能亢进症具有多种病因、临床表现和治疗方法。应用核素显像对甲状腺自身病变所致甲状腺功能亢进症病因进行正确的诊断,指导选择相对应合适的治疗方法。方法 319例临床拟诊甲亢患者,治疗前进行甲状腺显像(thyroid radionuclide imaging),对甲亢病因做分型。结果甲状腺显像特征分类Grave’s病(GD)259例(合并结节66例),81.2%;毒性腺瘤(TA)36例,11.3%;毒性多结节性甲状腺肿(TMNG)9例,2.8%;亚急性甲状腺炎15例,4.7%。结论甲状腺核素显像在甲状腺功能亢进症的分类和指导治疗中起重要的基础作用,可为临床提供合理及最佳的临床实践。

甲状腺功能性腺瘤及弥漫肿大的（131）~I消融作用

[目的]评价引起甲状腺功能亢进症自主功能性甲状腺瘤及弥漫肿大131I治疗的消融作用。[方法]182例甲亢患者,于131I治疗前进行甲状腺显像,诊断甲亢病因;131I治疗后6个月再次进行甲状腺显像,观察比较治疗前后131I的消融结果。[结果]182例患者中甲状腺自主性高功能腺瘤18例(9.89%),多结节性甲状腺肿伴甲亢5例(2.75%);弥漫性甲状腺肿大伴甲亢(Graves’病)159例(87.36%)。甲状腺自主性高功能腺瘤18例患者均治愈,有2例出现甲减。Graves’病一次治愈130例(81.8%),其中甲状腺功能正常99例(62.3%),早发甲减31例(19.5%);未愈29例(18.2%)。治疗前和131I消融后6个月甲状腺显像甲状腺质量明显缩小,分别为49.1g和26.9g。[结论]131I对甲状腺瘤及弥漫肿大有显著消融作用。